← Back

Oxford Science Enterprises

Europe HQ Seed Series-A Above Series A
Cheque range
£5M – £30M
Stages
Seed, Series A, Above Series A
Avg deals / year
5.5
Leads rounds
Yes
HQ
London
Fund type
Venture fund

01 · Thesis & focus

Oxford Science Enterprises a university-partnered venture firm, investing in early-stage life science, AI & software, and deep tech.

Sectors (3)

02 · Recent publicly announced deals

Fractile 🇬🇧 Series C · Nov 2026 First-cheque stage site ↗
Founders: Walter G.
FluoRok Series A · Nov 2026 First-cheque stage site ↗
Alethio Therapeutics Series A · Nov 2026 First-cheque stage site ↗
Oxford Quantum Circuits (OQC) Series C · Nov 2026 First-cheque stage site ↗
Genomics Series C · Nov 2026 First-cheque stage site ↗
Fractile 🇬🇧 Series C · Oct 2026 First-cheque stage site ↗
Founders: Walter G.
Salience Labs 🇬🇧 Series B · Oct 2026 · $125M First-cheque stage announcement ↗ site ↗

All-optical switches connecting GPUs across racks in AI data centers

Founders: Johannes F., Vaysh K., Wolfram P., Harish B.
OMass Therapeutics 🇬🇧 Series C · Oct 2026 · $310M First-cheque stage announcement ↗ site ↗

Oxford spinout developing small-molecule drugs for endocrine and immune diseases.

Founders: Idlir L., Jonathan H.

03 · Similar firms

Raising? See which European funds fit your round →